Alzheimer's disease and type 2 diabetes: Exploring the association to obesity and tyrosine hydroxylase

CNS and Neurological Disorders - Drug Targets

Volumn 11, Issue 4, 2012, Pages 482-489

  Priyadarshini, Medha ^a   Kamal, Mohammad A ^b   Greig, Nigel H ^c   Reale, Marcella ^d   Abuzenadah, Adel M ^b   Chaudhary, Adeel G A ^b   Damanhouri, Ghazi A ^b  

^a ALIGARH MUSLIM UNIVERSITY   (India)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^c NATIONAL INSTITUTE ON AGING   (United States)

^d UNIVERSITY OF CHIETI   (Italy)

Author keywords

Alzheimer's disease; Dementia; Insulin resistance; Metabolic syndrome; Neurodegeneration; Neuroinflammation; Obesity; Parkinson's disease; Type 2 diabetes mellitus; Tyrosine hydroxylase

Indexed keywords

ADIPOCYTOKINE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; AMYLOID PROTEIN; CYTOKINE; FATTY ACID; GLUCOCORTICOID; GLUCOSE; GLYCOGEN SYNTHASE KINASE; INSULIN; INSULIN RECEPTOR; SOMATOMEDIN C; TAU PROTEIN; TYROSINE 3 MONOOXYGENASE;

ALZHEIMER DISEASE; BODY MASS; DEMENTIA; DEPRESSION; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENDOCRINE DISEASE; ENZYME ACTIVATION; GLUCOSE INTOLERANCE; HUMAN; HYPERINSULINEMIA; INFLAMMATION; INSULIN RESISTANCE; MEMORY DISORDER; MILD COGNITIVE IMPAIRMENT; NITROSATIVE STRESS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; REVIEW; VASCULAR DISEASE;

EID: 84862523849     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152712800792767     Document Type: Review

References (111)

1. Kumar, S.; Singh, R.; Vasudeva, N.; Sharma, S. Acute and chronic animal models for the evaluation of anti-diabetic agents. Cardiovasc. Diabetol., 2012, 11(1), 9.
2. Kroner, Z. The relationship between alzheimer's disease and diabetes: type 3 diabetes? Altern. Med. Rev., 2009, 14(4), 373-379.
3. Jellinger, K.A. Alzheimer 100 - highlights in the history of Alzheimer research. J. Neural Transm., 2006, 113, 1603-1623.
4. Ballard, C.; Gauthier, S.; Corbett, A.; Brayne, C.; Aarsland, D.; Jones, E. Alzheimer's disease. Lancet, 2011, 377(9770), 1019-1031.
5. Li, L.; Holscher, C. Common pathological processes in Alzheimer disease and type 2 diabetes. A review. Brain Res. Rev., 2007, 56, 384-402.
6. Ahmed, I.; Goldstein, B.J. Cardiovascular risk in the spectrum of type 2 diabetes mellitus. Mt. Sinai J. Med., 2006, 73, 759-768.
7. Milionis, H.J.; Florentin, M.; Giannopoulos, S. Metabolic Syndrome and Alzheimer's disease: A link to a vascular hypothesis? CNS Spectr., 2008, 13(7), 606-613.
8. Banu, S.; Jabir, N.R.; Manjunath, C.N.; Shakil, S.; Kamal, M.A. Cpeptide and itscorrelation to parameters of insulin resistance in the metabolic syndrome. CNS Neurol. Disord. Drug Targets, 2011, 10(8), 921-927.
9. Luchsinger J.A.; Gustafson D.R. Adiposity, type 2 diabetes and Alzheimer's disease. J. Alzheimers Dis., 2009, 16(4), 693-704.
10. Poirier, P.; Giles, T.D.; Bray, G.A.; Hong, Y.; Stern, J.S.; Pi-Sunyer, F.X.; Eckel, R.H. Obesity and cardiovascular disease: Pathophysiology, evaluation, and effect of weight loss: An update of the 1997 American Heart Association scientific statement on obesity and heart disease from the Obesity Committee of the Council on Nutrition, PhysicalActivity, and Metabolism. Circulation, 2006, 113, 898-918.
11. Pi-Sunyer, F.X. The obesity epidemic: Pathophysiology and consequences of obesity. Obes. Res., 2002, 10, 97-104.
12. Naderali, E.K.; Ratcliffe, S.H.; Dale, M.C. Obesity and Alzheimer's disease: a link between body weight and cognitive function in old age. Am. J. Alzheimers Dis. Other Demen., 2010, 24(6), 445-449.
13. DeFronzo, R.A. Pharmacologic therapy for type 2 diabetes mellitus. Ann. Intern. Med., 2000, 133, 73-74.
14. Festa, A.; Williams, K.; D'Agostino, R. Jr.; Wagenknecht, L.E.; Haffner, S.M. The Natural course of {beta}- cell function in nondiabetic and diabetic individuals: The insulin resistance atherosclerosis study. Diabetes, 2006, 55, 1114-1120.
15. Reaven, G. Insulin resistance, type 2 diabetes mellitus, and cardiovascular disease: the end of the beginning. Circulation, 2005, 112, 3030-3032.
16. Hoa, A.J.; Rajib C.A.; Saharana, P.; DeGiorgioa, A.; Madsena, S.K.; Hibara, D.P.; Steina, J.L.; Beckerd, J.T.; Lopezf, O.L.; Togaa, A.W.; Thompsona, P.M.; The Alzheimer's Disease Neuroimaging Initiative (ADNI). Hippocampal volume is related to body mass index in Alzheimer's disease. Neuroreport, 2011, 22(1), 10-14.
17. Whitmer, R.A.; Gunderson, E.P.; Barrett-Connor, E.; Quesenberry, C.P., Jr.; Yaffe, K. Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ, 2005, 330(7504), 1360.
18. Anstey, K.J.; Cherbuin, N.; Budge, M.; Young, J. Body mass index in midlife and late-life as a risk factor for dementia: a meta-analysis of prospective studies. Obes. Rev., 2011, 12(5), e426-e437.
19. Razay, G.; Wilcock, G.K. Hyperinsulinaemia and Alzheimer's disease. Age Ageing., 1994, 23, 396-399.
20. Stolk, R.P.; Breteler, M.M.; Ott, A.; Pols, H.A.; Lamberts, S.W.; Grobbee, D.E.; Hofman, A. Insulin and cognitive function in an elderly population. The Rotterdam Study. Diabetes Care, 1997, 20, 792-795.
21. Ott, A.; Stolk, R.P.; van Harskamp, F.; Pols, H.A.; Hofman, A.; Breteler, M.M. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology, 1999, 53, 1937-1942.
22. Arvanitakis, Z.; Wilson, R.S.; Bienias, J.L.; Evans, D.A.; Bennett, D.A. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch. Neurol., 2004, 61, 661-666.
23. D'Ercole, A.J.; Ye, P.; Calikoglu, A.S.; Gutierrez-Ospina, G. The role of the insulin- like growth factors in the central nervous system. Mol. Neurobiol., 1996, 13, 227-255.
24. Martin, E.D.; Sánchez-Perez, A.; Trejo, J.L.; Martin-Aldana, J.A.; Cano Jaimez, M.; Pons, S.; Umanzor, C.A.; Menes, L.; White M.F.; Burks, D.J. IRS-2 Deficiency impairs NMDA receptordependent long-term potentiation. Cerebr. Cortex, 2011, doi:10.1093/cercor/bhr216.
25. Riederer, P.; Bartl J.; Laux, G.; Grunblatt, E. Diabetes type II: risk factor for depression-Parkinson-Alzheimer? Neurotox. Res., 2011, 19, 253-265.
26. de la Monte, S.M. Insulin resistance and Alzheimer's disease. BMB Rep., 2009, 42, 475-481.
27. Hildreth, K.L.; Van Pelt, R.E.; Schwartz, R.S. Obesity, Insulin resistance and Alzheimer's Disease. Obesity (Silver Spring), 2012, doi: 10.1038/oby.2012.19.
28. Craft, S.; Watson, G.S. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol., 2004, 3, 169-178.
29. Roriz-Filho, J.S.; Sá-Roriz, T.M.; Rosset, I.; Camozzato, A.L.; Santos, A.C.; Chaves, M.L.; Moriguti, J.C.; Roriz-Cruz, M. (Pre) diabetes, brain aging, and cognition. Biochim. Biophys. Acta, 2009, 1792(5), 432-443.
30. Sun, X.J.; Crimmins, D.L.; Myers, M.J.; Miralpeix, M.; White, M.F. Pleiotropic insulin signals are enInsulin resistance and AD Suzanne M. de la Monte 480 BMB reports ttp://bmbreports.org gaged by multisite phosphorylation of IRS-1. Mol. Cell. Biol., 1993, 13, 7418-7428.
31. Lam, K.; Carpenter, C.L.; Ruderman, N.B.; Friel, J.C.; Kelly, K.L. The phosphatidylinositol 3-kinase serine kinase phosphorylates IRS-1. Stimulation by insulin and inhibition by Wortmannin. J. Biol. Chem., 1994, 269, 20648-20652.
32. Halestrap, A.P.; Doran, E.; Gillespie, J.P.; O'Toole, A. Mitochondria and cell death. Biochem. Soc. Trans., 2000, 28, 170-177.
33. Dudek, H.; Datta, S.R.; Franke, T.F.; Birnbaum, M.J.; Yao, R.; Cooper, G.M.; Segal, R.A.; Kaplan, D.R.; Greenberg, M.E. Regulation of neuronal survival by the serine- threonine protein kinase Akt [see comments]. Science, 1997, 275, 661-665.
34. de la Monte, S.M.; Wands J.R. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. J. Alzheimers Dis., 2005, 7, 45-61.
35. Steen, E.; Terry, B.M.; Rivera, E.J.; Cannon, J.L.; Neely, T.R.; Tavares, R.; Xu, X.J.; Wands, J.R.; de la Monte, S.M. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease is this type 3 diabetes? J. Alzheimers Dis., 2005, 7, 63-80.
36. Rivera, E.J.; Goldin, A.; Fulmer, N.; Tavares, R.; Wands, J.R.; de la Monte, S.M. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J. Alzheimers Dis., 2005, 8, 247-268.
37. Li, L., Holscher, C. Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res. Rev., 2007, 56, 384-402.
38. Chen, G.J.; Xu, J.; Lahousse, S.A.; Caggiano, N.L.; de la Monte, S.M: Transient hypoxia causes Alzheimer-type molecular and biochemical abnormalities in cortical neurons: potential strategies for neuroprotection. J. Alzheimers Dis., 2003, 5, 209-228.
39. Mandelkow, E.M.; Stamer, K.; Vogel, R.; Thies, E.; Mandelkow, E. Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol. Aging, 2003, 24, 1079-1085.
40. Yamamoto, N.; Matsubara, T.; Sobue, K.; Tanida, M.; Kasahara, R.; Naruse, K.; Taniura, H.; Sato, T.; Suzuki, K. Brain insulin resistance accelerates Aß fibrillogenesis by inducing GM1 ganglioside clustering in the presynaptic membranes. J. Neurochem., 2012, 121(4), 619-628.
41. Yamagishi, S.; Nakamura, K.; Inoue, H.; Kikuchi, S.; Takeuchi, M. Serum or cerebrospinal fluid levels of glyceraldehyde-derived advanced glycation end products (AGEs) may be a promising biomarker for early detection of Alzheimer's disease. Med. Hypotheses, 2005, 64, 1205-1207.
42. Cornier, M.A.; Dabelea, D.; Hernandez, T.L.; Lindstrom, R.C.; Steig, A.J.; Stob, N.R.; Van Pelt, R.E.; Wang, H.; Eckel, R.H. The metabolic syndrome. Endocr. Rev., 2008, 29(7), 777-822.
43. Qiu, C.; Kivipelto, M.; von Strauss, E. Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin. Neurosci., 2009, 11, 111-128.
44. Ho, A.J.; Raji, C.A.; Becker, J.T.; Lopez, O.L.; Kuller, L.H.; Hua, X.; Lee, S.; Hibar, D.; Dinov, I.D.; Stein, J.L.; Jack Jr, C.R.; Weiner, M.W.; Toga, A.W.; Thompson, P.M.; The Cardiovascular Health Study; The ADNI. Obesity is linked with lower brain volume in 700 AD and MCI Patients. Neurobiol. Aging, 2010, 31(8), 1326-1339.
45. Raji, C.A.; Ho, A.J.; Parikshak, N.N.; Becker, J.T.; Lopez, O.L.; Kuller, L.H.; Hua, X.; Leow, A.D.; Toga, A.W.; Thompson, P.M. Brain structure and obesity. Hum. Brain Mapp., 2010, 31(3), 353-364.
46. Gazdzinski, S.; Millin, R.; Kaiser, L.G.; Durazzo, T.C.; Mueller, S.G.; Weiner, M.W.; Meyerhoff, D.J. BMI and neuronal integrity in healthy, cognitively normal elderly: a proton magnetic resonance spectroscopy study. Obesity (Silver Spring), 2010, 18(4), 743-748.
47. Beydoun, M.A.; Beydoun, H.A.; Wang, Y. Obesity and central obesity as risk factors for incident dementia and its subtypes: a systematic review and meta-analysis. Obes. Rev., 2008, 9, 204-218.
48. Bertram, L.; Heekeren, H. Obesity and the brain: a possible genetic link. Alzheimer's Res. Ther., 2010, 2, 27.
49. Craft, S. The role of metabolic disorders in alzheimer disease and vascular dementia. Arch. Neurol., 2009, 66(3), 300-305.
50. Bravata, D.M.; Wells, C.K.; Concato, J.; Kernan, W.N.; Brass, L.M.; Gulanski, B. I. Two measures of insulin sensitivity provided similar information in a US population. J. Clin. Epidemiol., 2004, 57(11), 1214-1217.
51. Bray, G.A.; Lovejoy, J.C.; Smith, S.R.; DeLany, J.P.; Lefevre, M.; Hwang, D.; Ryan, D.H.; York, D.A. The influence of different fats and fatty acids on obesity, insulin resistance and inflammation. J. Nutr., 2002, 132(9), 2488-2491.
52. Vessby, B.; Unsitupa, M.; Hermansen, K.; Riccardi, G.; Rivellese, A.A.; Tapsell, L.C.; Nälsén, C.; Berglund, L.; Louheranta, A.; Rasmussen, B.M.; Calvert, G.D.; Maffetone, A.; Pedersen, E.; Gustafsson, I.B.; Storlien, L.H.; KANWU Study. Substituting dietary saturated for monounsaturated fat impairs insulin sensitivity in healthy men and women: the KANWU Study. Diabetologia, 2001, 44(3), 312-319.
53. Lopez, S.; Bermúdez, B.; Pacheco, Y.M.; Villar, J.; Abia, R.; Muriana, F.J. Distinctive postprandial modulation of beta cell function and insulin sensitivity by dietary fats: monounsaturated compared with saturated fatty acids. Am. J. Clin. Nutr., 2008, 88(3), 638-644.
54. Frankola, K.A.; Greig, N.H.; Luo, W.; Tweedie, D. Targeting TNF-α to elucidate and ameliorate neuroinflammation in neurodegenerative diseases. CNS Neurol. Disord. Drug Targets. 2011, 10(3), 391-403.
55. Puig, K.L.; Floden, A.M.; Adhikari, R.; Golovko, M.Y.; Combs, C.K. Amyloid precursor protein and proinflammatory changes are regulated in brain and adipose tissue in a murine model of high fat diet-induced obesity. PLoS ONE, 2012, 7(1), e30378.
56. Lee, Y.H.; Martin, J.M.; Maple, R.L.; Tharp, W.G.; Pratley, R.E. Plasma amyloid- beta peptide levels correlate with adipocyte amyloid precursor protein gene expression in obese individuals. Neuroendocrinology, 2009, 90, 383-390.
57. Sommer, G.; Kralisch, S.; Lipfert, J.; Weise, S.; Krause, K.; Jessnitzer, B.; Lössner, U.; Blüher, M.; Stumvoll, M.; Fasshauer, M. Amyloid precursor protein expression is induced by tumor necrosis factor alpha in 3T3- L1 adipocytes. J. Cell Biochem., 2009, 108, 1418-1422.
58. Johnston, J.M.; Greco, S.J.; Hamzelou, A.; Ashford, J.W.; Tezapsidis, N. Repositioning leptin as a therapy for Alzheimer's disease. Therapy, 2011, 8(5), 481-490.
59. Rothman, S.M.; Mark, P. Mattson. Adverse stress, hippocampal networks, and alzheimer's disease. Neuromol. Med., 2010, 12(1), 56-70.
60. Solas, M.; Aisa, B.; Mugueta, M.C.; Del Rio, J.; Tordera, R.M.; Ramirez, M.J. Interactions between age, stress and insulin on cognition: implications for alzheimer's disease. Neuropsychopharmacology, 2010, 35, 1664-1673.
61. Sotiropoulos, I.; Cerqueira, J.J.; Catania, C.; Takashima, A.; Sousa, N.; Almeida, O.F.X. Stress and glucocorticoid footprints in the brain- the path from depression to Alzheimer's disease. Neurosci. Biobehav. Rev., 2008, 32, 1161-1173.
62. Nelson, D.H. Regulation of glucocorticoid release. Am. J. Med., 1972, 53, 590-594.
63. Berton, O.; Nestler, E.J. New approaches to antidepressant drug discovery: beyond monoamines. Nat. Rev. Neurosci., 2006, 7, 137-151.
64. Dhikav, V.; Anand, K.S. Glucocorticoids may initiate Alzheimer's disease: a potential therapeutic role for mifepristone (RU-486). Med. Hypotheses, 2007, 68, 1088-1092.
65. Amatruda, J.M.; Livingston, J.N.; Lockwood, D.H. Cellular mechanisms in selected states of insulin resistance: human obesity, glucocorticoid excess and chronic renal failure. Diabetes Metab. Rev., 1985, 1, 293-317.
66. Delaunay, F.; Khan, A.; Cintra, A.; Davani, B.; Ling, Z.C.; Andersson, A.; Ostenson, C.G.; Gustafsson, J.; Efendic, S.; Okret, S. Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids. J. Clin. Invest., 1997, 100, 2094-2098.
67. Lees, A.J.; Hardy, J.; Revesz, T. Parkinson's disease. Lancet, 2009, 373, 2055-2066.
68. Nagatsu, T.; Sawada, M. Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects. J. Neural Transm., 2007, 72, 113-120.
69. Zafeiriou, D.I.; Willemsen, M.A.; Verbeek, M.M.; Vargiami, E.; Ververi, A.; Wevers, R. Tyrosine hydroxylase deficiency with severe clinical course. Mol. Genet. Metab., 2009, 97(1), 18-20.
70. Spillantini, M.G.; Goedert, M. The a-Synucleinopathies: Parkinson's disease, dementia with lewy bodies, and multiple system atrophy. Ann. NY Acad. Sci., 2000, 920, 16-27.
71. Hamilton, R.L. Lewy bodies in Alzheimer's disease: Aneuropathological review of 145 cases using a-Synuclein immunohistochemistry. Brain Pathol., 2000, 10, 378-384.
72. Cardoso, S.; Correia, S.; Santos, R.X.; Carvalho, C.; Santos, M.S.; Oliveira, C.R.; Perry, G.; Smith, M.A.; Zhu, X.; Moreira, P.I. Insulin is a two-edged knife on the brain. J. Alzheimers Dis., 2009, 18(3), 483-507.
73. Reale, M.; Greig, N.H.; Kamal, M.A. Peripheral chemo-cytokine profiles in Alzheimer's and Parkinson's diseases. Mini Rev. Med. Chem., 2009, 9(10), 1229-1241.
74. Cooper, J.R.; Bloom, F.E.; Roth, R.H. In: The Biochemical Basis Of Neuropharmacology; Oxford University Press: New York, 1996, p. 230.
75. Zhou, Q-Y.; Qualfe, C.J.; Palmiter, R.D. Targeted disruption of the tyrosine hydroxylase gene reveals that catecholamines are required for mouse fetal development. Nature, 1995, 374, 640-643.
76. Moran, L.B.; Graeber, M.B. Towards a pathway definition of Parkinson's disease: a complex disorder with links to cancer, diabetes and inflammation. Neurogenetics, 2008, 9, 1-13.
77. Cereda, E.; Barichella, M.; Pedrolli, C.; Klersy, C.; Cassani, E.; Caccialanza, R.; Pezzoli, G. Diabetes and risk of parkinson's disease: a systematic review and meta- analysis. Diabetes Care, 2011, 34, 2614-2623.
78. Loscalzo, J.; Kohane, I.; Barabasi, A.L. Human disease classification in the postgenomic era: a complex systems approach to human pathobiology. Mol. Syst. Biol., 2007, 3, 124.
79. Bosco, D.; Plastino, M.; Cristiano, D.; Colica, C.; Ermiom C.; De Bartolom M.; Mungari, P.; Fonte, G.; Consoli, D.; Consoli, A.; Fava, A. Dementia is associated with Insulin Resistance in patients with Parkinson's Disease. J. Neurol. Sci., 2012, 315(1-2), 39-43.
80. Xu, Q.; Park, Y.; Huang, X.; Hollenbeck, A.; Blair, A.; Schatzkin, A.; Chen, H. Diabetes and risk of Parkinson's disease. Diabetes Care, 2011, 34(4), 910-915.
81. Driver, J.A.; Smith, A.; Buring, J.E.; Gaziano, J.M.; Kurth, T.; Logroscino, G. Prospective cohort study of type 2 diabetes and the risk of Parkinson's disease. Diabetes Care, 2008, 31(10), 2003-2005.
82. D'Amelio, M.; Ragonese, P.; Callari, G.; Di Benedetto, N.; Palmeri, B.; Terruso, V.; Salemi, G.; Famoso, G.; Aridon, P.; Savettieri, G. Diabetes preceding Parkinson's disease onset. A case-control study. Parkinsonism Relat. Disord., 2009, 15(9), 660-664.
83. Hu, G.; Jousilahti, P.; Bidel, S.; Antikainen, R.; Tuomilehto, J. Type 2 Diabetes and the Risk of Parkinson's Disease. Diabetes Care, 2007, 30(4), 842-847.
84. Ma, H.I.; Kim, J.H.; Chu, M.K.; Oh, M.S.; Yu, K.H.; Kim, J.; Hahm, W.; Kim, Y.J.; Lee, B.C. Diabetes mellitus and druginduced Parkinsonism: a case-control study. J. Neurol. Sci., 2009, 284(1-2), 140-143.
85. Morris, J.K.; Bomhoff, G.L.; Gorres, B.K.; Davis, V.A.; Kim, J.; Lee, P.P.; Brooks, W.M.; Gerhardt, G.A.; Geiger, P.C.; Stanford, J.A. Insulin resistance impairs nigrostriatal dopamine function. Exp. Neurol., 2011, 231(1), 171-180.
86. Rönnemaa, E.; Zethelius, B.; Sundelöf, J.; Sundström, J.; Degerman-Gunnarsson, M.; Lannfelt, L.; Berne, C.; Kilander, L. Glucose metabolism and the risk of Alzheimer's disease and dementia: a population-based 12 year follow-up study in 71- yearold men. Diabetologia, 2009, 52, 1504-1510.
87. Rönnemaa, E.; Zethelius, B.; Sundelöf, J.; Sundström, J.; Degerman-Gunnarsson, M.; Lannfelt, L.; Berne, C.; Kilander, L. Impaired insulin secretion increases the risk of Alzheimer disease. Neurology, 2008, 71, 1065-1071.
88. Karakelides, H.; Irving, B.A.; Short, K.R.; O'Brien, P.; Nair, K.S. Age, obesity, and sex effects on insulin sensitivity and skeletal muscle mitochondrial function. Diabetes, 2010, 59, 89-97.
89. Chen, H.; O'Reilly, E.J.; Schwarzschild, M.A.; Ascherio, A. Peripheral inflammatory biomarkers and risk of Parkinson's disease. Am. J. Epidemiol., 2008, 167, 90-95.
90. Chiba, M.; Suzuki, S.; Hinokio, Y.; Hirai, M.; Satoh, Y.; Tashiro, A.; Utsumi, A.; Awata, T.; Hongo, M.; Toyota, T. Tyrosine hydroxylase gene microsatellite polymorphism associated with insulin resistance in depressive disorder. Metabolism, 2000, 49(9), 1145-1149.
91. Song, I.U.; Kim, J.S.; Chung, S.W.; Lee, K.S. Is there an association between the level of highsensitivity C-reactive protein and idiopathic Parkinson's disease? A comparison of Parkinson's disease patients, disease controls and healthy individuals. Eur. Neurol., 2009, 62, 99-104.
92. Blanchard-Fillion, B.; Souza, J.M.; Friel, T.; Jiang, G.C.T.; Vrana, K.; Sharov, V.; Barron, L.; Schoneich, C.; Quijano, C.; Alvarez, B.; Radi, R.; Przedborski, S.; Fernando, G.S.; Horwitz, J.; Ischiropoulos, H. Nitration and inactivation of tyrosine hydroxylase by peroxynitrite. J. Biol. Chem., 2001, 276(49-7), 46017-46023.
93. Goldstein, L.B.; Gorelick, P.B.; Howard, G.; Kittner, S.J.; Manolio, T.A.; Whisnant, J.P.; Wolf, P.A. American Heart Association Prevention Conference. IV. Prevention and Rehabilitation of Stroke. Risk factors. Stroke, 1997, 28, 1507-1517.
94. Vermeer, S.E.; Prins, N.D.; den Heijer, T.; Hofman, A.; Koudstaal, P.J.; Breteler, M.M. Silent brain infarcts and the risk of dementia and cognitive decline. N. Engl. J. Med., 2003, 348, 1215-1222.
95. Qiu, C.; Hu, G.; Kivipelto, M.; Laatikainen, T.; Antikainen, R.; Fratiglioni, L.; Jousilahti, P.; Tuomilehto, J. Association of blood pressure and hypertension with the risk of Parkinson disease: the National FINRISK Study. Hypertension, 2011, 57, 1094-1100.
96. Hu, G.; Antikainen, R.; Jousilahti, P.; Kivipelto, M.; Tuomilehto, J. Total cholesterol and the risk of Parkinson disease. Neurology, 2008, 70, 1972-1979.
97. Tabrez, S.; Jabir, N.R.; Shakil, S.; Greig, N.H.; Alam, Q.; Abuzenadah, A.M.; Damanhouri, G.A.; Kamal, M.A. A synopsis on the role of tyrosine hydroxylase in parkinson's disease. CNS Neurol. Disord. Drug Targets, 2012, 11(2). 10-10.
98. Martorana, A.; Mori, F.; Esposito, Z.; Kusayanagi, H.; Monteleone, F.; Codeca, C.; Sancesario, G.; Bernardi, G.; Koch, G. Dopamine modulates cholinergic cortical excitability in alzheimer's disease patients. Neuropsychopharmacology, 2009, 34, 2323-2328.
99. Bohnen, N.I.; Albin, R.L. The cholinergic system and Parkinson disease. Behav. Brain Res., 2011, 221(2), 564-673.
100. Blokland, A. Acetylcholine: a neurotransmitter for learning and memory? Brain Res. Brain Res. Rev., 1995, 21, 285-300.
101. Cao, Y.J.; Surowy, C.S.; Puttfarcken, P.S. Different nicotinic acetylcholine receptor subtypes mediating striatal and prefrontal cortical [3H]dopamine release. Neuropharmacology, 2005, 48, 72-79.
102. Di Cara, B.; Panayi, F.; Gobert, A.; Dekeyne, A.; Sicard, D.; De Groote, L.; Millan, M.J. Activation of dopamine D1 receptors enhances cholinergic transmission and social cognition: a parallel dialysis and behavioural study in rats. Int. J. Neuropsychopharmacol., 2007, 10, 383-399.
103. Millan, M.J.; Di Cara, B.; Dekeyne, A.; Panayi, F.; De Groote, L.; Sicard, D.; Cistarelli, L.; Billiras, R.; Gobert, A. Selective blockade of dopamine D(3) versus D(2) receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis. J. Neurochem., 2007, 100, 1047-1061.
104. Murray, A.M.; Weihmueller, F.B.; Marshall, J.F.; Hurtig, H.I.; Gottleib, G.L.; J Joyce, J.N. Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism. Ann. Neurol., 1995, 37, 300-312.
105. Pizzolato, G.; Chierichetti, F.; Fabbri, M.; Cagnin, A.; Dam, M.; Ferlin, G.; Battistin, L. Reduced striatal dopamine receptors in Alzheimer's disease: single photon emission tomography study with the D2 tracer [123I]-IBZM. Neurology, 1996, 47, 1065-1068.
106. Kemppainen, N.; Laine, M.; Laakso, M.P.; Kaasinen, V.; Nagren, K.; Vahlberg, T. Hippocampal dopamine D2 receptors correlate with memory functions in Alzheimer's disease. Eur. J. Neurosci., 2003, 18, 149-154.
107. Martorana, A.; Stefani, A.; Palmieri, M.G.; Esposito, Z.; Bernardi, G.; Sancesario, G.; Pierantozzi, M. L-: dopa modulates motor cortex excitability in Alzheimer's disease patients. J. Neural Transm. 2008, 115, 1313-1319.
108. Kumar, U.; Patel, S.C. Immunohistochemical localization of dopamine receptor subtypes (D1R-D5R) in Alzheimer's disease brain. Brain Res., 2007, 1131, 187-196.
109. Torack, R.M.; Morris, J.C. Tyrosine hydroxylase-like (TH) immunoreactivity in Parkinson's disease and Alzheimer's disease. J. Neural Transm. Park. Dis. Dement. Sect., 1992, 4(2), 165-171.
110. McMillan, P.J.; White, S.S.; Franklin, A.; Greenup, J.L.; Leverenz, J.B.; Raskin, A.M.; Szot, P. Differential response of the central noradrenergic nervous system to the loss of locus coeruleus neurons in Parkinson's disease and Alzheimer's disease. Brain Res., 2011, 10(1373), 240-252.
111. Rao, F.; Zhang, L.; Wessel, J.; Zhang, K.; Wen, G.; Kennedy, B.P.; Rana, B.K.; Das, M.; Rodriguez-Flores, J.L.; Smith, D.W.; Cadman, P.E.; Salem, R.M.; Mahata, S.K.; Schork, N.J.; Taupenot, L.; Ziegler, M.G.; O'Connor, D.T. Tyrosine hydroxylase, the rate-limiting enzyme in catecholamine biosynthesis discovery of common human genetic variants governing transcription, autonomic activity, and blood pressure in vivo. Circulation, 2007, 116(9), 993-1006.